Immune-based therapies are revolutionising the treatment of previously intractable cancers. In particular, therapies using chimeric antigen receptor (CAR) T cells have yielded unprecedented clinical responses in patients with B cell leukemia. However, the majority of cancers, in particular solid tumours, fail to respond to CAR T cell therapy. This proposal will take advantage of cutting-edge preclinical tumour models and innovative approaches to enhance CAR cell therapies in cancer.
|Effective start/end date||1/12/19 → 31/12/23|
- T cell immunotherapy
- solid tumours
- natural killer cells
- protein tyrosine phosphatase (PTP)
- tumour immunology